Investigational drug · Phase 2
ST-067
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer, Solid Tumor, Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 15, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "ST-067"
First trial start
2021
Aug 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ST-067", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer
- Solid Tumor
- Melanoma
- Renal Cell Carcinoma
- Triple-negative Breast Cancer
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma
- MSI-High
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Melanoma · Kidney cancer (renal cell carcinoma) · Head and neck cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ST-067" as an intervention, largest first.
Simcha IL-18, Inc.Industry
NCT04787042 · 316 participants (planned) · Start Aug 6, 2021 · Primary completion Jun 30, 2025
Drug: ST-067; Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA] and 1 more · For: Cancer; Solid Tumor; Melanoma and 6 more
Sites: Scottsdale, Arizona; Denver, Colorado; New Haven, Connecticut · 6 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06492707 · 40 participants (planned) · Start Sep 23, 2024 · Primary completion Oct 1, 2027
Drug: Decoy-resistant interleukin-18 · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia and 1 more
Sites: Seattle, Washington
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT07098364 · 33 participants (planned) · Start Dec 27, 2025 · Primary completion Oct 4, 2030
Drug: Vevoctadekin; Lisocabtagene Maraleucel · For: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma and 9 more
Sites: Seattle, Washington
University of WashingtonAcademic, hospital or other
NCT06588660 · 1 participants · Start Dec 18, 2024 · Primary completion Feb 14, 2025
Drug: Vevoctadekin; Teclistamab · For: Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Sites: Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- EmactuzumabPhase 32 trials
Roche (Genentech) · Cancer, TGCT
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials
MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.